End-of-day quote
Other stock markets
|
||
- EGP | - |
03/03 | Ibnsina Pharma Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
05/02 | Ibnsina Pharma(CASE:ISPH) added to EGX 30 Index | CI |
Sales 2024 * | 36.64B 769M 64.15B | Sales 2025 * | 44.09B 925M 77.18B | Capitalization | 2.45B 51.42M 4.29B |
---|---|---|---|---|---|
Net income 2024 * | 417M 8.75M 730M | Net income 2025 * | 417M 8.75M 730M | EV / Sales 2024 * | 0.17 x |
Net Debt 2024 * | 3.65B 76.59M 6.39B | Net Debt 2025 * | 3.56B 74.76M 6.24B | EV / Sales 2025 * | 0.14 x |
P/E ratio 2024 * |
8.1
x | P/E ratio 2025 * |
6.31
x | Employees | - |
Yield 2024 * |
1.6% | Yield 2025 * |
3.18% | Free-Float | 61.4% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 18/00/18 | |
Chief Executive Officer | - | 18/00/18 | |
Momen Gomaa
DFI | Director of Finance/CFO | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | - | |
Chief Executive Officer | - | 18/00/18 | |
Chief Executive Officer | - | 18/00/18 |
1st Jan change | Capi. | |
---|---|---|
-29.67% | 10.84B | |
-28.54% | 6.06B | |
+7.42% | 6.04B | |
-11.41% | 5.86B | |
-0.73% | 4.69B | |
+52.19% | 4.29B | |
-12.31% | 3.61B | |
-13.25% | 3.33B | |
-6.93% | 3.01B |